Evaluation of blood rheology by patients with acute ischemic stroke with Mexidol administration

doi:https://doi.org/10.17116/jnevro201911903276

Journal: . 2019;119(3‑2): 76‑82

DOI: 10.17116/jnevro201911903276

Read: 6899 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Evaluation of blood rheology by patients with acute ischemic stroke with Mexidol administration. . 2019;119(3‑2):76‑82. (In Russ.)
https://doi.org/10.17116/jnevro201911903276

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски (S.S. Korsakov Journal of Neurology and Psychiatry (special issues))

Использование инфографики авторами научных работ

Close metadata

Recommended articles:

Relationship between stroke-associated pneumonia and long-term outcomes of ischemic stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):57-61

Fortelyzin for acute ischaemic stroke treatment: an open, prospective, non-interventional, observational study FORPI registry. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(12):43-59

Abstract:

To study rheological properties of blood in patients with acute ischemic stroke treated with mexidol. Material and methods. Sixty patients with acute stroke, including 32 patients who received mexidol (500 mg/IV/20 days) and 28 people who received magnesium sulfate (2000 mg/IV/20 days) were examined. The control group included 20 people without a cardiovascular pathology. Blood rheology (viscosity of whole blood, plasma viscosity, hematocrit, aggregation and deformability of erythrocytes, fibrinogen level) was evaluated in patients three times: for the first 12 hours, 3—5 days and 18—20 days after hospitalization. Results. Hyperviscosity syndrome was observed in all patients with stroke. A significant decrease in blood viscosity was found in patients treated with mexidol: in the 3–5th day at low shear rates and in the 18—20th day at 3—100 s–1 shear rates. Significant differences in hematocrit (p=0.026) and fibrinogen levels (p=0.017) in patients treated with different drugs were found in the 18—20th day of the disease. Higher erythrocyte deformability index was recorded in patients treated with mexidol in the 3—5th day at shear rates of 90 and 890 s–1, in the 18—20th day at shear rates of 90—360 s–1. Conclusion. The study confirms the impact of mexidol on the fluidity of blood during the acute cerebral ischemia and shows its efficacy in reducing blood viscosity, decreasing the level of hematocrit and fibrinogen, increasing the deformability of erythrocytes.

Keywords:

acute ischemic stroke

rheological parameters of blood

blood viscosity

erythrocytes deformability

mexidol (ethylmethylhydroxypyridine succinate)

treatment of stroke

Close metadata

References:

Feigin V, Forouzanfar M, Krishnamurthi R, Mensah G, Connor M, Bennett D, Moran A, Sacco R, Anderson L, Truelsen T, O’Donnell M, Venketasubramanian N, Barker-Collo S, Lawes C, Wang W, Shinohara Y, Witt E, Ezzati M, Naghavi M, Murray C. Global and regional burden of stroke during 1990—2010: findings from the Global Burden of Disease Study 2010. The Lancet. 2014;383(9913):245-255. https://doi.org/10.1016/S0140-6736(13)61953-4
Shandalin VA, Fonyakin AV, Geraskina LA, Suslina ZA. Prognostic Factors of Cardiovascular Complications After Ischemic Stroke. Kardiologiia. 2015;11:61-68. (In Russ.) https://doi.org/10.18565/cardio.2015.11.61-68
Azhermacheva M, Burkova K, Plotnikov D, Alifirova V, Solovtsov M. Endothelial dysfunction in acute ischemic stroke. Journal of the Neurological Sciences. 2013;333:242. https://doi.org/10.1016/j.jns.2013.07.941
Dashe JF. Hyperviscosity and stroke. In: Bogousslavsky J., Caplan L. (eds.) Uncommon causes of stroke, 3’ ed. New York: Cambridge University Press; 2008. https://doi.org/10.1017/cbo9780511544897.048
Sigle JP, Buser A. Hyperviscosity syndrome. Blood. 2011;117:5:1446-1448. https://doi.org/10.1182/blood-2010-04-279869
Fasano A, Sequeira A. Hemorheology and Hemodynamics. Hemomath. 2017;1-77. https://doi.org/10.1007/978-3-319-60513-5_1
Mohandas N, Gallagher P. Red cell membrane: past, present, and future. Blood. 2008;112(10):3939-3948. https://doi.org/10.1182/blood-2008-07-161166
Tsuda K. Oxidative Stress and Membrane Fluidity of Red Blood Cells in Hypertensive and Normotensive Men. International Heart Journal. 2010;51(2):121-124. https://doi.org/10.1536/ihj.51.121
Revnic C, Revnic F. The impact of oxidative stress upon membrane fluidity and cytoplasmic lipids peroxidation in red blood cells from hypertensive patients of different ages with stroke. Alzheimer’s & Dementia. 2012;8(4): 295. https://doi.org/10.1016/j.jalz.2012.05.795
Manno S, Takakuwa Y, Mohandas N. Identification of a functional role for lipid asymmetry in biological membranes: Phosphatidylserine-skeletal protein interactions modulate membrane stability. Proc Natl Acad Sci USA. 2002;99:1943-1948. https://doi.org/10.1073/pnas.042688399
Ginsberg M. Neuroprotection for ischemic stroke: Past, present and future. Neuropharmacology. 2008;55(3):363-389. https://doi.org/10.1016/j.neuropharm.2007.12.007
Sergeyev DV, Piradov MA, Maksimova MYu, Domashenko MA, Sergeyeva AN, Okhtova F. New possibilities of neuroprotection in ischemic stroke. Neurology, neuropsychiatry, Psychosomatics. 2011;0(4):56-63. (In Russ.) https://doi.org/10.14412/2074-2711-2011-348
Stakhovskaya LV, Tyutyumova EA, Fedin AI. Modern approaches to neuroprotective treatment of ischemic stroke. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2017;117(8):75-80. (In Russ.) https://doi.org/10.17116/jnevro20171178275-80
Yanishevvsky SN, Tsygan NV, Golokhvastov SYu, Andreev RV, Litvinenko IV, Karpova OS, Yakovleva VA. Modern strategies of protection of hypoxic-ischemic brain damage. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2017;12(2):78-86. (In Russ.) https://doi.org/10.17116/jnevro201711712278-86
Stakhovskaya LV, Shamalov NA, Khasanova DR, Melnikova EV, Agafiina AS, Golikov KV, Bogdanov EI, Yakupova AA, Roshkovskaya LV, Lukinykh LV, Lokshtanova TM, Poverennova IE, Shepankevich LA. Results of a randomized double blind multicenter placebo-controlled, in parallel groups trial of the efficacy and safety of prolonged sequential therapy with mexidol in the acute and early recovery stages of hemispheric ischemic stroke (EPICA). Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2017;117(3-2):55-65. (In Russ.) https://doi.org/10.17116/jnevro20171173255-65
Chefranova ZhYu, Makotrova TA, Udachin VA, Koledintseva EV. Efficacy of mexidol in the combination with thrombolytic therapy in patients with ischemic stroke. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2012;112(4):49-52. (In Russ.)
Voronina T.A. Mexidol: the spectrum of pharmacological effects. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2012;12:86-90. (In Russ.) https://doi.org/10.17116/jnevro201211722286-90
Torshin IYu, Gromova OA, Sardaryan IS, Fedotova LE. Comparative chemoreactome analysis of mexidol. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2017;1(2):75-84. (In Russ.) https://doi.org/10.17116/jnevro20171171275-84
Tanashyan MM, Ladoga OV, Antonova KV. Cerebrovascular diseases: perspectives of pathogenetic metabolic haemangiocorrective treatment. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova; 2015;9:71-75. (In Russ.) https://doi.org/10.17116/jnevro20151159170-75